Esmeralda Casas-Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esmeralda Casas-Silva has a total of 259 co-authors. Here are the top co-authors by number of shared publications:
- John Otridge
Frederick National Laboratory for Cancer Research, Frederick, Maryland
28 shared publications - Anthony R. Kerlavage
Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland
19 shared publications - Erika Kim
Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland
19 shared publications - Jill S. Barnholtz Sloan
National Cancer Institute, Bethesda, USA
19 shared publications - Tanja M. Davidsen
Center for Biomedical Informatics and Information Technology, NCI, Rockville, Maryland
19 shared publications - Todd Pihl
Frederick National Laboratory for Cancer Research, Frederick, Maryland
19 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
CRDC Program Collaborator Names from NCI Cancer Research Data Commons: Lessons Learned and Future State
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessCRDC Program Collaborator Names from NCI Cancer Research Data Commons: Lessons Learned and Future State
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
CRDC Program Collaborator Names from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessCRDC Program Collaborator Names from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from NCI Cancer Research Data Commons: Lessons Learned and Future State
CRDC Dataset Citations by Year
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from NCI Cancer Research Data Commons: Lessons Learned and Future State
CRDC Dataset Citations by Year
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1. from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
A list of web resources for CRDC data commons
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1. from NCI Cancer Research Data Commons: Resources to Share Key Cancer Data
A list of web resources for CRDC data commons
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from NCI Cancer Research Data Commons: Lessons Learned and Future State
Cancer Research Data Commons (CRDC) displaying each component of the CRDC infrastructure.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from NCI Cancer Research Data Commons: Lessons Learned and Future State
Cancer Research Data Commons (CRDC) displaying each component of the CRDC infrastructure.
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 33 (3) , 663-669
A novel analysis methodology for assessment of re-identification risks for the National Cancer Institute cancer registry privacy preserving record linkage technique
Objective: The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) supports efforts to address critical challenges in advancing cancer research. As part of this effort, NCI sponsored the development of a privacy-preserving record linkage (PPRL) software that transforms identifying patient information into multiple tokens through a set of cryptographically secure keyed hash functions. This project aims to evaluate the PPRL software in the perspective of re-identification risks and propose effective strategies to sufficiently mitigate these risks. Materials and Methods: To achieve the goals, we developed a novel re-identification risk assessment framework, based on token frequency analysis, to estimate the privacy impact of hashed tokens shared for record linkage. We assessed privacy risk through empirical analysis on a state-level voter registration database, a public dataset commonly used for re-identification, under various scenarios. These scenarios are defined based on several factors, including the size of the dataset used for linkage and a group size parameter that determines when an adversary can claim that a record has been re-identified. Results: We found that the re-identification risk based on frequency analysis attack is approximately 0.0002 (ie, 2 patients out of 10 000 are potentially identifiable) under reasonable adversarial settings, with a group size parameter of k = 12 and a dataset size of 400 000 patients. Additionally, our analysis reveals a negative correlation between dataset size and re-identification risk. Discussion: Re-identification risk is deemed low for the new NCI PPRL software. Token frequency analysis provides a reliable estimate of the re-identification risk in token-based PPRL tools.
- 27 October 2025
- Published by Oxford University Press (OUP) in Journal of the American Medical Informatics Association
- Vol. 33 (3) , 663-669
A novel analysis methodology for assessment of re-identification risks for the National Cancer Institute cancer registry privacy preserving record linkage technique
Objective: The National Cancer Institute (NCI), part of the National Institutes of Health (NIH) supports efforts to address critical challenges in advancing cancer research. As part of this effort, NCI sponsored the development of a privacy-preserving record linkage (PPRL) software that transforms identifying patient information into multiple tokens through a set of cryptographically secure keyed hash functions. This project aims to evaluate the PPRL software in the perspective of re-identification risks and propose effective strategies to sufficiently mitigate these risks. Materials and Methods: To achieve the goals, we developed a novel re-identification risk assessment framework, based on token frequency analysis, to estimate the privacy impact of hashed tokens shared for record linkage. We assessed privacy risk through empirical analysis on a state-level voter registration database, a public dataset commonly used for re-identification, under various scenarios. These scenarios are defined based on several factors, including the size of the dataset used for linkage and a group size parameter that determines when an adversary can claim that a record has been re-identified. Results: We found that the re-identification risk based on frequency analysis attack is approximately 0.0002 (ie, 2 patients out of 10 000 are potentially identifiable) under reasonable adversarial settings, with a group size parameter of k = 12 and a dataset size of 400 000 patients. Additionally, our analysis reveals a negative correlation between dataset size and re-identification risk. Discussion: Re-identification risk is deemed low for the new NCI PPRL software. Token frequency analysis provides a reliable estimate of the re-identification risk in token-based PPRL tools.
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Cross referencing to genomic and imaging resources for individual cases. Example of cross-referencing (A) on the Clinical tab of PDC’s Explore page; B, on the Clinical tab and External References section of PDC study summary pages.
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Cross referencing to genomic and imaging resources for individual cases. Example of cross-referencing (A) on the Clinical tab of PDC’s Explore page; B, on the Clinical tab and External References section of PDC study summary pages.
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Figure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
PDC study summary page offering a comprehensive overview of both data and metadata.
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Documentation resources in the PDC
- Open Access
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Table 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons
- 20 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from NCI’s Proteomic Data Commons: A Cloud-Based Proteomics Repository Empowering Comprehensive Cancer Analysis through Cross-Referencing with Genomic and Imaging Data
Available data types in the proteomic data commons